- SK pharmteco announces a $6.1 million investment in its Rancho Cordova, California facility to expand lab and CGMP-kilo-scale capabilities for Solid-Phase Peptide Synthesis (SPPS) and purification.
- The new expansion is scheduled to begin operations in January 2026 for the lab and the second half of 2026 for the kilo-scale facility, enhancing U.S. peptide CDMO capabilities.
SK pharmteco, a global contract development and manufacturing organization (CDMO), has announced a $6.1 million investment to expand its Rancho Cordova, California, facility. The funding will establish a new laboratory and CGMP-kilo-scale facility dedicated to Solid-Phase Peptide Synthesis (SPPS) and purification, addressing the growing demand for U.S.-based peptide development and domestic clinical and commercial manufacturing.
The expansion will provide an integrated pathway for peptide process development, from lab-scale experimentation to kilo-scale CGMP production, including the crucial purification stage. This complements SK pharmteco’s existing development and manufacturing capabilities in the United States and follows its $260 million investment in a small molecule and peptide production facility in South Korea announced last year.
“The investment in our California facility represents a key milestone in our strategic growth and demonstrates an unwavering dedication to the domestic biopharma sector. Peptides are a vital and rapidly advancing therapeutic category. This project highlights our ongoing commitment to furthering their development and manufacturing.”
Joerg Ahlgrimm, CEO of SK pharmteco
The expansion comes as the peptide industry faces challenges in efficiently converting complex molecules into high-purity, large-volume batches. By integrating lab and kilo-scale SPPS with purification, SK pharmteco aims to mitigate bottlenecks and supply delays, supporting faster and more reliable production for clients. The laboratory is scheduled to become operational in January 2026, with the kilo-scale facility following in the second half of the year.
